D.-M. Shen et al. / Bioorg. Med. Chem. Lett. 21 (2011) 76–81
81
058845.; (d) Kodra, J. T.; Jørgensen, A. S.; Andersen, B.; Behrens, C.; Brand, C. L.;
Christensen, I. T.; Guldbrandt, M.; Jeppesen, C. B.; Knudsen, L. B.; Madsen, P.;
Nishimura, E.; Sams, C.; Sidelmann, U. G.; Pedersen, R. A.; Lynn, F. C.; Lau, J. J.
Med. Chem. 2008, 51, 5387; (e) Madsen, P.; Kodra, J. T.; Behrens, C.; Nishimura,
E.; Jeppesen, C. B.; Pridal, L.; Andersen, B.; Knudsen, L. B.; Valcarce-Aspegren, C.;
Guldbrandt, M.; Christensen, I. T.; Jørgensen, A. S.; Ynddal, L.; Brand, C. L.;
Bagger, M. A.; Lau, J. J. Med. Chem. 2009, 52, 2989.
References and notes
1. Ettaro, L.; Songer, T. J.; Zhang, P.; Engelgau, M. M. Pharmacoeconomics 2004, 22,
149.
2. (a) Sarabu, R.; Tiley, J. Ann. Rep. Med. Chem. 2005, 40, 167; (b) Nourparvar, A.;
Bulotta, A.; Di-Mario, U.; Perfetti, R. Trends Pharmacol. Sci. 2004, 25, 86.
3. (a) Zhang, B. B.; Moller, D. B. Curr. Opin. Chem. Biol. 2000, 4, 461; (b) Jiang, G.;
Zhang, B. B. Am. J. Physiol. 2003, 284, E671; (c) Sloop, K. W.; Michael, M. D. Drugs
Fut. 2004, 29, 835.
4. (a) Brand, C. L.; Rolin, B.; Jorgensen, P. N.; Svendsen, I.; Kristensen, J. S.; Holst, J.
J. Diabetologia 1994, 37, 985; (b) Brand, C. L.; Jorgensen, P. N.; Knigge, U.;
Warberg, J.; Svendsen, I.; Kristensen, J. S.; Holst, J. J. Am. J. Physiol. 1995, 269,
E469; (c) Brand, C. L.; Jorgensen, P. N.; Svendsen, I.; Holst, J. J. Diabetes 1996, 45,
1076; (d) Brand, C. L.; Hansen, B.; Groneman, S.; Boysen, M.; Holst, J. J. Diabetes
2000, 49, A81; (e) Liang, Y.; Osborne, M. C.; Monia, B. P.; Bhanot, S.; Gaarde, W.
A.; Reed, C.; She, P.; Jetton, T. L.; Demarest, K. T. Diabetes 2004, 53, 410; (f)
Sloop, K. W.; Cao, J. X.-C.; Siesky, A. M.; Zhang, H. Y.; Bodenmiller, D. M.; Cox, A.
L.; Jacobs, S. J.; Moyers, J. S.; Owens, R. A.; Showalter, A. D.; Brenner, M. B.; Raap,
A.; Gromada, J.; Berridge, B. R.; Monteith, D. K. B.; Porksen, N.; McKay, R. A.;
Monia, B. P.; Bhanot, S.; Watts, L. M.; Michael, M. D. J. Clin. Invest. 2004, 113,
1571.
10. (a) Shen, D-M.; Shu, M.; Chapman, K. T. Org. Lett. 2000, 2, 2789; (b) Shen, D.-M.;
Shu, M.; Mills, S. G.; Chapman, K. T.; Malkowitz, L.; Springer, M. S.; Gould, S. L.;
DeMartino, J. A.; Siciliano, S. J.; Kwei, G. Y.; Carella, A.; Carver, G.; Holmes, K.;
Schlief, W. A.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M. D.;
Emini, E. A. Bioorg. Med. Chem. Lett. 2004, 14, 935. and two following Letters.
11. The system of MeCN/DCM appears uniquely effective in separating pyrazole
isomers. It was used for separating pyrazole isomers in Ref. 10b also.
12. All intermediates described here showed expected 1H NMR and LC–MS. All
isomeric pyrazole intermediates were identified by NOE difference spectra. All
final products showed expected LC–MS and some were characterized by 1H
NMR.
13. Qureshi, S. A.; Candelore, M. R.; Xie, D.; Yang, X.; Tota, L. M.; Ding, V. D.-H.; Li,
Z.; Bansal, A.; Miller, C.; Cohen, S.; Jiang, G.; Brady, E.; Saperstein, R.; Duffy, J. L.;
Tata, J. R.; Chapman, K. T.; Moller, D. E.; Zhang, B. B. Diabetes 2004, 53, 3267.
14. Jones, P. F.; Lappert, M. F. J. Chem. Soc., Chem. Commun. 1972, 526.
15. The Claisen reaction mixture for 3 and 21 was heated under reflux in THF for
10 min followed by standing at room temperature overnight versus room
temperature only for all other Claisen reactions.
5. Petersen, K. F.; Sullivan, J. T. Diabetologia 2001, 44, 2018.
6. (a) DeMong, D. E.; Miller, M. W.; Lachowicz, J. E. Ann. Rep. Med. Chem. 2008, 43,
119; (b) Kurukulasuriya, R.; Link, J. T. Expert Opin. Ther. Patents 2005, 15(12),
1739.
7. Shen, D.-M.; Zhang, F.; Brady, E. J.; Candelore, M. R.; Dallas-Yang, Q.; Ding, V.
D.-H.; Dragovic, J.; Feeney, W. P.; Jiang, G.; McCann, P. E.; Mock, S.; Qureshi, S.
A.; Saperstein, R.; Shen, X.; Tamvakopoulos, C.; Tong, X.; Tota, L. M.; Wright, M.
J.; Yang, X.; Zheng, S.; Chapman, K. T.; Zhang, B. B.; Tata, J. R.; Parmee, E. R.
Bioorg. Med. Chem. Lett. 2005, 15, 4564.
8. (a) Ling, A.; Plewe, M. B.; Truesdale, L. K.; Lau, J.; Madsen, P.; Sams, C.; Behrens,
C.; Vagner, J.; Christensen, I. T.; Lundt, B. F.; Sidelmann, U. G.; Thøgersen, H. U.S.
Patent 6503,949, 2003; Chem. Abstr. 2001, 134, 4764.; (b) Lau, J.; Behrens, C.;
Sidelmann, U. G.; Knudsen, L. B.; Lundt, B.; Sams, C.; Ynddal, L.; Brand, C. L.;
Pridal, L.; Ling, A.; Kiel, D.; Plewe, M. B.; Shi, S.; Madsen, P. J. Med. Chem. 2007,
50, 113.
9. (a) After the completion of our studies described here, benzimidazoles, indoles,
aminothiazoles, pyridazines, and several other cyclic structures as additional
conformationally constrained replacements of ureas such 1 have appeared:
Lau, J.; Christensen, I. T.; Madsen, P.; Behrens, C.; WO 2003 053938.; (b) Lau, J.;
Christensen, I. T.; Madsen, P.; Block, P.; Behrens, C.; Kodra, J. T.; Nielsen, P. E.
WO 2004 002480.; (c) Madsen, P.; Lau, J.; Kodra, J. T.; Christensen, I. T. WO2005
16. Jorgensen, A. S.; Christensen, I. T. Kodra, J. T.; Madsen, P.; Behrens, C.; Sams, C.;
Lau, J. WO 2002 000612.
17. Madsen, P.; Lau, J.; Ling, A. WO 2002 040444.
18. The full characterization of the hGCGR mice and their response to known
antagonists has been reported: (a) Shiao, L.-L.; Cascieri, M. A.; Trumbauer, M.;
Chen, H.; Sullivan, K. A. Transgenic Res. 1999, 8, 295; (b) Dallas-Yang, Q.; Shen,
X.; Strowski, M.; Brady, E.; Saperstein, R.; Gibson, R. E.; Szalkowski, D.;
Candelore, M. R.; Fenyk-Melody, J. E.; Parmee, E. R.; Zhang, B. B.; Jiang, G. Eur. J.
Pharmacol. 2004, 501, 225.
19. Fish, L. R.; Gilligan, M. T.; Humphries, A. C.; Ivarsson, M.; Ladduwahetty, T.;
Merchant, K. J.; O’Connor, D.; Patel, S.; Philipps, E.; Vargas, H. M.; Hutson, P. H.;
MacLeod, A. M. Bioorg. Med. Chem. Lett. 2005, 15, 3665.
20. Pharmacodynamic experiments in rhesus monkeys: overnight fasted monkeys
were dosed either with vehicle or test compound 26 4 h prior to glucagon
challenge. At time zero, the animals were treated with glucagon (15 lg/kg im)
and plasma glucose was monitored every 10 min. The data were platted as the
change of plasma glucose relative to time zero for each group.